Koji Takei

Post-hoc analysis of MCI186-17, the extension study to MCI186-16, the confirmatory double-blind, parallel-group, placebo-controlled study of edaravone in amyotrophic lateral sclerosis

Fumihiro Takahashi, Koji Takei, Kikumi Tsuda et al. · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · 2017 · 39 citations · Full text

Neurological Disorder, Post-hoc Analysis, Extension Study +20

Post-hoc analysis of randomised, placebo-controlled, double-blind study (MCI186-19) of edaravone (MCI-186) in amyotrophic lateral sclerosis

Koji Takei, Fumihiro Takahashi, X. Shawn Liu et al. · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · 2017 · 32 citations · Full text

Als Functional Rating, Neurodegenerative Diseases, Amyotrophic Lateral Sclerosis +15

Pharmacokinetic profile of edaravone: a comparison between Japanese and Caucasian populations

Yoshinobu Nakamaru, Shuji Kinoshita, Atsuhiro Kawaguchi et al. · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · 2017 · 23 citations · Full text

Post-hoc analysis of open-label extension period of study MCI186-19 in amyotrophic lateral sclerosis

Koji Takei, Kikumi Tsuda, Fumihiro Takahashi et al. · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · 2017 · 21 citations · Full text